Risk of second malignancy after cutaneous T-cell lymphoma

Arlene F. Kantor(Philadelphia University), Joseph F. Fraumeni(National Institutes of Health), Eric C. Vonderheid(Ashford and St Peter's Hospitals NHS Foundation Trust), Rochelle E. Curtis(National Institutes of Health), Eugene J. Van Scott(Abington Memorial Hospital)

Cancer

April 15, 1989

10.1002/1097-0142(19890415)63:8<1612::aid-cncr2820630828>3.0.co;2-c

Cited by 105

Related Papers

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer

|Nature Genetics|2007|1.5k

Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)

|Blood|2007|1.4k

Replicating genotype–phenotype associations

|Nature|2007|1.4k

Treatment of Cutaneous T-Cell Lymphoma by Extracorporeal Photochemotherapy

|New England Journal of Medicine|1987|1.2k

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

|Nature Genetics|2007|1.1k